Document is current
Any future updates will be listed below
-
Authors
Khosroyani, Homma M. https://orcid.org/0000-0001-9709-6712
Klug, Lillian R. https://orcid.org/0000-0003-0520-8241
Heinrich, Michael C. https://orcid.org/0000-0003-3790-0478
- License Information
-
More Information
Article History
Accepted: 23 November 2022
First Online: 6 January 2023
Declarations
:
: The authors received no specific funding for this work. The general work of Michael C. Heinrich has been supported by grants from the Department of Veterans Affairs (1 I01 BX005358-01A1) and the National Institutes of Health National Cancer Institute (1 R21 CA263400-01), and by philanthropic donations from the GIST Cancer Research Fund and the Jonathan David Foundation.
: Homma M. Khosroyani and Lillian R. Klug have no conflicts of interest that are directly relevant to the content of this article. Michael C. Heinrich has the following conflicts of interest: honoraria: Novartis; consulting or advisory role: Novartis, Blueprint Medicines, Deciphera, Theseus Pharmaceuticals; and patents, royalties, other intellectual property: patent on treatment of GIST licensed to Novartis (Inst).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: HMK, LRK, and MCH have all made substantial contributions to the content of the article, which include writing, reviewing, and editing of the manuscript before submission. In addition, HMK was responsible for the creation of all the figures and tables in the article.
